Proactive Investors - Run By Investors For Investors

Allergy Therapeutics publishes pre-clinical data on malaria and flu vaccines

The studies were carried out through Allergy’s Bencard Adjuvant Systems division.
picture of mosquito
Malaria is one of the diseases Allergy is targeting

Allergy Therapeutics (LON:AGY) has published data in peer-reviewed journals from two preclinical studies analysing its immuno-therapy platform as a potential vaccine against malaria and the flu.

The two papers reported that Allergy’s immunotherapy Pollinex platform, microcrystalline tyrosine (MCT), both alone and in an adjuvant (immune system booster) system, had broad applications and boosted protection compared to conventional adjuvants.

The studies were carried out through Allergy’s Bencard Adjuvant Systems division. 

Manuel Llobet, chief executive, said: "These publications underpin the strategy for our Bencard Adjuvant Systems division, which focuses on extending the use of MCT and VLP (virus-like particle) in further developing vaccines against unmet needs, and new and emerging infectious diseases that require an effective depot adjuvant."

View full AGY profile View Profile

Allergy Therapeutics PLC Timeline

Related Articles

mri scanner
September 12 2018
IXICO is actively supporting the hunt for breakthrough treatments for Alzheimer’s, Parkinson’s, Huntington’s and multiple sclerosis
cough
October 19 2018
Respiratory syncytial virus causes the common cold, for which there is no effective cure.
bacteria
September 20 2018
Following the disappointment of its DMD treatment over summer, Summit is leveraging its Discuva platform to develop new antibiotics, which doctors are in desperate need of

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use